Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change
Denis S. Smirnov(University of California San Diego), Douglas Galasko(University of Minnesota), Robert A. Rissman(University of Southern California), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Annie Hiniker(University of Southern California), Thomas K. Karikari(University of Pittsburgh), Henrik Zetterberg(University of Wisconsin–Madison), Nicholas J. Ashton(King's College London), David P. Salmon(University of California San Diego), Joel Simrén(University of Gothenburg)
Cited by 229
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k